These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 20519717)

  • 1. Visualizing the landscape of selection biomarkers in current phase III oncology clinical trials.
    Sikorski R; Yao B
    Sci Transl Med; 2010 Jun; 2(34):34ps27. PubMed ID: 20519717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parallel paths to predictive biomarkers in oncology: Uncoupling of emergent biomarker development and phase III trial execution.
    Sikorski R; Yao B
    Sci Transl Med; 2009 Dec; 1(10):10ps11. PubMed ID: 20368158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A standardization method to adjust for the effect of patient selection in phase II clinical trials.
    Mazumdar M; Fazzari M; Panageas KS
    Stat Med; 2001 Mar; 20(6):883-92. PubMed ID: 11252010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalizing cancer care: updates on head and neck cancer.
    de Souza JA; Cohen EE
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1219-22. PubMed ID: 19761425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating biomarkers in clinical trials.
    Buyse M; Michiels S; Sargent DJ; Grothey A; Matheson A; de Gramont A
    Expert Rev Mol Diagn; 2011 Mar; 11(2):171-82. PubMed ID: 21405968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phase III trials in oncology].
    Imadalou K; Cvitkovic E
    Bull Cancer; 1999 Feb; 86(2):143-7. PubMed ID: 10066944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A strategic framework for novel drug development in multiple myeloma.
    Anderson KC; Hannah AL; Pazdur R; Farrell AT
    Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022
    [No Abstract]   [Full Text] [Related]  

  • 12. Factors that influence the recruitment of patients to Phase III studies in oncology: the perspective of the clinical research associate.
    Wright JR; Crooks D; Ellis PM; Mings D; Whelan TJ
    Cancer; 2002 Oct; 95(7):1584-91. PubMed ID: 12237929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?
    Ratain MJ; Glassman RH
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6545-8. PubMed ID: 18006752
    [No Abstract]   [Full Text] [Related]  

  • 14. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seeking informed consent to cancer clinical trials: describing current practice.
    Brown RF; Butow PN; Ellis P; Boyle F; Tattersall MH
    Soc Sci Med; 2004 Jun; 58(12):2445-57. PubMed ID: 15081196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Being in a research study.
    Kunches L; Sax P
    AIDS Clin Care; 1996 Jan; 8(1):5-6. PubMed ID: 11363057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience.
    Faratian D; Kay C; Robson T; Campbell FM; Grant M; Rea D; Bartlett JM
    Histopathology; 2009 Nov; 55(5):587-93. PubMed ID: 19912364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying the usefulness of PD biomarkers in Phase 2 screening trials of oncology drugs.
    Holmgren E
    Stat Med; 2008 Oct; 27(24):4928-38. PubMed ID: 18618429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Difficulties with conducting clinical trials in France].
    Zannad F; Plétan Y
    Therapie; 2001; 56(4):341-7. PubMed ID: 11677850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.